Vaccine research: Can DNA vaccines get a boost from cytokines?
Mark Boaz and Richard Jefferys
IAVI Report – February/April 2003
Report from the annual Keystone conference on HIV Vaccine Development (28 March-4 April 2003, Banff, Alberta).
Headline stories reported from three corporate players: VaxGen, which discussed results from its recently completed Phase III trial; Merck, with updates on its Phase I clinical trials and announcing a new partnership with Aventis Pasteur; and Wyeth-Aherst, describing a strategy that may improve the usefulness of DNA-based vaccines.